eXoZymes, Inc.
EXOZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$157.23M
Close$
$0.21
95.9% downside
Current Fair Value
95.9% downsideOvervalued by 95.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $157.23 Million |
|---|---|
| Enterprise Value | $152.31 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.09 |
| Beta | 3.19 |
| Outstanding Shares | 8,660,246 |
Return
| Return on Equity | -278.89% |
|---|---|
| Return on Assets | -127.67% |
| Return on Invested Capital | -35.00% |
Valuation & Multiples
| P/E Ratio | -4.38 |
|---|---|
| PEG | -19.92 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -68.37 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About eXoZymes, Inc.
32 employees
CEO: Michael Heltzen eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Tech...